Anantha Shekhar, MD, PhD
Associate Vice President of Research for University Clinical Affairs
Anantha Shekhar, MD, PhD, a nationally recognized researcher at Indiana University School of Medicine and director of Indiana’s largest statewide research organization leads the IU School of Medicine’s research enterprise.
Dr. Shekhar holds several leadership posts at IU and IU Health and was named executive associate dean for research affairs in August 2015, overseeing all research-related activities at the IU School of Medicine. He is one of six executive associate deans who make up the school’s executive leadership team with Dean Jay L. Hess, MD, PhD.
Dr. Shekhar is the founding director of the Indiana Clinical and Translational Sciences Institute (Indiana CTSI), a statewide institute within Indiana University School of Medicine, supported by a CTSA grant from the US National Institutes of Health and established in 2008 as a joint partnership of Indiana University, Purdue University, the University of Notre Dame and numerous life sciences businesses and community organizations. The Institute’s mission is to assist in the rapid translation of new discoveries into novel treatments.
In addition to his roles with the Indiana CTSI and IU School of Medicine, Dr. Shekhar is the Associate Vice President for University Affairs, Indiana University; Executive Vice President of Academic Affairs for Clinical Research, IU Health; August M. Watanabe Professor of Medical Research, Professor of Psychiatry, Neurobiology and Pharmacology & Toxicology at IU School of Medicine.
Titles & Appointments
- Executive Associate Dean for Research Affairs
- August M. Watanabe Professor of Medical Research
- Distinguished Professor of Psychiatry
- Professor of Neurobiology
- Professor of Pharmacology and Toxicology
Dr. Shekhar’s areas of expertise include basic and clinical research on the effects of stress, stress-induced psychiatric and medical conditions, and clinical psychopharmacology. He conducts numerous foundation supported studies, including being the principal investigator of the longitudinal study of disease risk factors in Indiana population, supported by the Fairbanks Institute of Indiana. His translational work has centered on developing novel treatment targets for major psychiatric disordres in patients with panic disorder and schizophrenia. He is also Director of the Neuroscience Clinical Research Center at Indiana University School of Medicine, a fully staffed inpatient psychiatric research unit, for the last eight years, where many novel early phase psychopharmacology discovery and drug development studies are conducted in partnership with the pharmaceutical and biotech industry.